Myelodysplastic syndromes: pathobiology and clinical management. - 36 (2nd ed.)

Written by a team of leading authorities in pathogenesis, diagnostic techniques, and clinical management strategies in myelodysplastic syndrome (MDS), this text provides a concise, easy-to-follow review of the advances in the science, classification, diagnosis, and management of the condition.

An ideal source for hematologists, oncologists, and cancer researchers, this Second Editionfeatures:

• a new eight-page color insert
• 200 color and black-and-white illustrations
• reworked content organized into three sections: MDS epidemiology and biology; diagnosis, classification, and prognosis; and MDS therapy
• thoroughly updated chapters reflecting a shift from the topical focus as dictated by the evolution of the field

New topics in Myelodysplastic Syndrome include:

• del(5q) and 5q-syndrome, CMML, and MDS-MPD overlap syndrome
• the reborn DNA methyltransferase inhibiting nucleoside analogs
• the diagnosis of chronic myelomonocytic leukemia and other MDS cases with myeloproliferative features
• the role of mitochondria and the potential importance of iron overload in MDS
• global genomics approaches, such as cDNA expression arrays, array-based comparative genomic hybridization, and single nucleotide polymorphism array
• the role of abnormal mitochondrial ferritin accumulation and other mitochondrial metabolic anomalies in MD
• other disease-associated alterations, such as abnormalities of B lymphocyte populations in MD
• three recently approved drugs: azacitidine, lenalidomide, and decitabine